Pathology of cyclodiode laser: a series of nine enucleated eyes

P A McKelvie, M J Walland

Aim: To study the histological effects of cyclodiode laser treatment in humans, and to compare these findings with the clinical course, treatment response, complications, and indications for enucleation.

Method: Detailed histological examination of nine enucleation specimens was undertaken in conjunction with a retrospective review of patient case notes.

Results: Retreatments had been undertaken in three cases. Although all globes showed damage to pars plicata, intact ciliary processes within the treatment zone were present in all cases. Pars plana injury was also noted in two thirds of cases. Inflammation was mild. Ciliary epithelial proliferation was seen in most cases with increasing time following treatment, in a disorganised pattern, without replication of the ciliary epithelial bilayer. No regeneration of the ciliary processes with fibrovascular cores was found. The three patients with good IOP control at enucleation had all had multiple diode treatments. Neither phthisis nor sympathetic ophthalmia was seen.

Conclusions: Diode laser cyclophotocoagulation produces very characteristic injury to pars plicata, which frequently extends into pars plana, but with only mild persisting inflammation. Ciliary processes are, however, frequently spared within the treatment zone and may account for early or late treatment failure.

CYCLODESTRUCTIVE THERAPIES IN THE PAST HAVE INCLUDED CYCLOOCRYOTHERAPY, WHICH IS RECOGNISED TO HAVE SIGNIFICANT MORTALITY. THIS INCLUDES PHTHISIS IN UP TO 12% OF TREATED EYES, RETINAL DETACHMENT, DESTRUCTION OF VISUAL ACUITY IN 60%, SYMPATHETIC OPHTHALMIA, INFLAMMATION THAT IS DIFFICULT TO CONTROL, SUBRETINAL FIBROSIS, LENS SUBLUXATION, ANTERIOR SEGMENT NECROSIS, NEUROTROPHIC CORNEAL ULCER, AND CATARACT. CYCLOCYTOPHEXYX IS A SPOT SIZE OF 7–8 mm BECAUSE OF THE SPREADING EFFECT, COMPARED WITH 1 mm FOR LASER.

RESULTS

The globes from nine enucleations of patients who had received cyclodiode laser were studied. Details are listed in Table 1. All patients were white with four females and five males. Age ranged from 31–80 years (median 65 years). All patients received diode laser therapy (Oculight SLx laser and G-probe, Iris Medical Instruments, Mountain View, CA, USA) with three patients receiving two or more treatments (Table 1). Diode therapy ranged from 180°–360° with power ranging from 1500 mW to 2200 mW and application duration ranging from 1500 to 2100 ms (Table 1). The time to enucleation ranged from 2 weeks to 4 years 1 month after diode (median 7 months). Causes of glaucoma were neovascular glaucoma in four, chronic open angle glaucoma in one, chronic angle closure following penetrating keratoplasty in one, epithelial downgrowth in two, and absolute pseudoexfoliation glaucoma in one.

Pathology

Pars plicata

Pars plicata damage was seen in all nine patients. This injury was characteristic for diode laser allowing recognition of such treatment, even before the clinical history was known. The...
Table 1  Clinical features and histopathology of globes with diode laser cyclophotocoagulation

<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>Cause of glaucoma</th>
<th>Type of treatment</th>
<th>Time of treatment prior to enucleation</th>
<th>Clinical response</th>
<th>Pars plicata injury</th>
<th>Pars plana injury</th>
<th>Other complications</th>
<th>Phthisis</th>
<th>Reason for enucleation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F/80</td>
<td>Neovascular (CRVO)</td>
<td>Diode 360°</td>
<td>8 months</td>
<td>IOP 78→22</td>
<td>Moderate</td>
<td>Not affected</td>
<td>–</td>
<td>No</td>
<td>Perforated microbial keratitis; high IOP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40 x 1500 ms x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blind, painful, high IOP</td>
</tr>
<tr>
<td>2</td>
<td>F/64</td>
<td>Absolute PXF</td>
<td>Diode 360°</td>
<td>5 months</td>
<td>IOP 44→19</td>
<td>Moderate to severe</td>
<td>Severe</td>
<td>–</td>
<td>No</td>
<td>Recurrent high IOP, rapidly enlarging cystic bleb</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40 x 1500 ms x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>3</td>
<td>F/64</td>
<td>Epithelial downgrowth</td>
<td>Diode 180° 4-10 o’clock</td>
<td>12 months</td>
<td>IOP 56→10</td>
<td>Severe</td>
<td>Mild</td>
<td>Scleral damage</td>
<td>No</td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>post PK ×2; sutured PCIOL</td>
<td>23 burns x 1500 ms x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>4</td>
<td>M/65</td>
<td>Chronic angle closure</td>
<td>Diode ×3</td>
<td>2 years 1 month</td>
<td>IOP 40 @ 4 months</td>
<td>Moderate to severe</td>
<td>Moderate</td>
<td>Scleral damage</td>
<td>No</td>
<td>Painful, with unrelieved inferior herpes simplex virus keratitis (IOP controlled)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>glaucoma after penetrating keratoplasty.</td>
<td>#1 270° 12-9 o’clock, 30 x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>#2 180° 10-4 o’clock, 20 x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>#3 180° 3-9 o’clock, 2000 mW x 1500 ms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>5</td>
<td>M/71</td>
<td>R COAG</td>
<td>Diode 270° 3-12 o’clock</td>
<td>7 months</td>
<td>IOP 48→50 @ 3 and 4 months</td>
<td>Moderate to severe</td>
<td>Moderate</td>
<td>Necrosis of iris base, apposed to angle</td>
<td>No</td>
<td>High IOP, total hyphaema, blood stained cornea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2200 mW x 18 shots</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blind, painful, total retinal detachment</td>
</tr>
<tr>
<td>6</td>
<td>M/44</td>
<td>Neovascular</td>
<td>Diode 270° 12-9 o’clock</td>
<td>4 months</td>
<td>IOP 42→20; Iris base necrosis</td>
<td>Moderate</td>
<td>Not affected</td>
<td>Scleral damage</td>
<td>No</td>
<td>Recurrent inflammation, tective tumour, blind painful eye</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2000 ms x 1700-2000 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>7</td>
<td>M/74</td>
<td>Neovascular post plaque for choroidal MM, failed L trab.</td>
<td>Diode 180° 10-4 o’clock</td>
<td>4 years 1 month</td>
<td>IOP response poor; 40+ at enucleation</td>
<td>Mild</td>
<td>Not affected</td>
<td>–</td>
<td>No</td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>8</td>
<td>F/31</td>
<td>Neovascular, tractional</td>
<td>Diode ×4</td>
<td>#1 16 months</td>
<td>IOP 26→21</td>
<td>Moderate to severe</td>
<td>Mild</td>
<td>Iris necrosis; Scleral damage</td>
<td>No</td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>retinal detachment</td>
<td>#1 inf 180° 22 x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(surgery including silicone oil), chronic uveitis</td>
<td>#2 lat 180° 20 x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>#3 3-12 o’clock 1510 mW x 2100 ms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>#4 360° 1750-2000 mW x 1500-2000 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td>9</td>
<td>M/75</td>
<td>R traumatic aphakia,</td>
<td>Diode ×2</td>
<td>#1 7 months</td>
<td>IOP 42→16, but 35 @ 6 weeks</td>
<td>Moderate to severe</td>
<td>Mild</td>
<td>–</td>
<td>No</td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>epithelial downgrowth</td>
<td>#1 Inf 180° 2000 mW x 1500 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>post 2° ACIOL</td>
<td>#2 Nasal 180° 2000 mW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Persistent pain due to corneal decompensation despite IOP control</td>
</tr>
</tbody>
</table>

*Clinical response is measured as IOP (mm Hg); 1°1500 mW = 1500 mW x 1500 ms.
CRVO = central retinal vein occlusion, PXF = pseudoexfoliation, PK = penetrating keratoplasty, PCIOL = posterior chamber intraocular lens, COAG = chronic open angle glaucoma, MM = malignant melanoma, Trab = trabeculectomy, ACIOL = anterior chamber intraocular lens.
damage comprised destruction of pigmented and non-pigmented ciliary epithelium and capillaries in the ciliary processes with pigment clumping, coagulative necrosis, and extensive destruction of ciliary muscle with moderate reduction in vascularity (Fig 1A and B). Injury was severe in two, moderate to severe in four, moderate in two, and mild in one. All of the moderately to severely affected cases had unequal damage around the circumference of treated areas with some foci showing total loss of ciliary processes but other foci with some sparing of some ciliary processes anteriorly, posteriorly, or centrally (Fig 1B). In three cases, a small amount of residual outer longitudinal muscle was noted. Some proliferation of non-pigmented epithelium over the surface of the necrotic masses was seen (Fig 1C), but this was only mild in cases with short intervals to enucleation (<7 months). The proliferation was always disorganised with masses of flattened epithelium with no reconstitution of ciliary processes with fibrovascular core and normal bilayered epithelial architecture. Vessels were sparse in the damaged pars plicata even at over 4 years, the longest time since treatment.

Pars plana injury
Pars plana injury was seen in six patients with complete sparing in three. Patient 2 has been previously reported by us. Damage consisted of loss of normal epithelium, pigment clumping, and destruction of muscle and most vessels. Two were graded as severe, one moderate, and three mild. In one of the severe cases (patient 2), the pars plana was extensively damaged (Fig 2) but adjacent pars plicata was totally spared over 180°. Some epithelial proliferation in disorganised masses was seen in cases with longer intervals to enucleation. The outer longitudinal muscle was spared in most cases.

Iris root
Iris root was damaged in three of the eight cases where this could be assessed (patient 1 lost iris tissue as a result of corneal perforation before enucleation). All patients with iris injury had neovascular glaucoma on histopathology, although one had a history of chronic open angle glaucoma (patient 5). The iris root for about 2 mm was totally necrotic with loss of iris pigment, muscle, and vessels (Fig 3) and this was contiguous with adjacent severe injury to pars plicata.

Sclera
Sclera in the path of the laser showed damage in three cases (patients 4, 6, and 8). Two of these patients had had multiple (three to four) diode treatments. The damaged sclera showed scarring with increased fibroblast density and increased vascularity in the area (Fig 4).

Perivascular lymphocytes were seen in sclera and episclera, with pigment seen in macrophages around vessels in two patients. No difference in scleral pigmentation was evident between cases with and without scleral injury.

Inflammation
Inflammation in the ciliary body was only seen in a minority of cases (33%) (patients 3, 7, 8). In each case, this may have been due to confounding factors. The first had undergone penetrating keratoplasty, cataract extraction, and posterior chamber intraocular lens placement with moderate iridocyclitis related to the haptic and subsequent epithelial ingrowth. The second had had 131I plaque therapy for choroidal malignant melanoma (but with persisting intermittent episodes of clinically evident inflammation) and a later cataract extraction. Patient 8 had clinical chronic uveitis. Mild perivascular lymphocytic infiltration was noted in sclera and episclera in the three patients with scleral injury. The remaining patients had no inflammation in the uvea or sclera.

Phthisis
None of the globes was phthisical.

Correlation of number of treatments and power with IOP at time of enucleation
The three patients with normal IOP at enucleation had all had multiple treatments with at least one of these at higher power (2000 mW). The other six patients with high IOP at
enucleation had a single treatment, with power of 1500 mW in four and higher power (1700–2200 mW) in the other two.

DISCUSSION
This study undertakes retrospective review of nine globes enucleated following cyclodiode procedures. Most of these eyes were removed because of problems directly related to raised IOP. This creates a potential for selection bias in this series, in that the eyes examined are often treatment failures, and their histopathological findings may be different from those from the successful eyes, which are not available to examine. However, at least three eyes with diode therapy (Nos 4, 8, and 9) in this study had successful control of IOP at enucleation, and the pathological findings in these cases are not qualitatively different from the other six diode cases (Table 1).

Cyclodiode produces very characteristic injury with focal damage and minimal inflammation. Pars plicata is usually severely affected with non-specific destruction of ciliary pigmented and non-pigmented epithelium and capillaries in the ciliary processes. This damage to the ciliary processes is presumed to result in reduced aqueous production and lowering of IOP. However, loss of ciliary processes is often incomplete, with sparing of some processes within the field of treatment. This may explain both a persistently elevated IOP in some patients, and that control may be achieved with retreatment, by filling in treatment gaps. The sparing of processes is presumably a function of spot size and recommended spacing of burns with the standard footplate.

Some epithelial regeneration in pars plicata was noted after diode therapy, and was more marked with increasing time since treatment. However, this epithelium, which was always disorganised and lacked a well developed pigment epithelial layer, may have been non-functional from a secretory viewpoint, as the normal architecture of ciliary processes with
8, at 2 weeks—and the level of inflammation was slight post-treatment enucleation was examined in our study—case 8. It may be responsible for the decrease, although the clinical unexplained, but it has been postulated that early inflammation involves a profound decrease in IOP at enucleation (cases 4, 8, and 9) all had more than one, and in one case four, diode laser treatments, including higher power for at least one of the retreatments. However, even these cases showed some sparing of ciliary processes.

Despite initial control of IOP, a late rise in IOP was seen in a number of cases (1, 2, 6, 8, 9) some months after treatment. In all of these cases, there were foci of spared ciliary processes within the treatment areas, when multiple sections of the globe were examined, and even circumferential treatments spared some ciliary processes (cases 1, 2, 8). It is interesting to note that the three cases with well controlled IOP at enucleation (cases 4, 8, and 9) all had more than one, and in one case four, diode laser treatments, including higher power for at least one of the retreatments. However, even these cases showed some sparing of ciliary processes.

Pars plana is affected in two thirds of diode cases (6/9), and severely in 20%. Damage to pars plana was unintentional given the footplate design of the G-probe, which matches the curve of the globe, abutting the limbus to centre the fibre optic 1.2 mm behind the limbus. However, the site of the ciliary body is not uniform for all eyes, and the position in relation to the limbus may vary with axial length. We have previously reported a case of pars plana injury due to diode laser and have proposed that an increase in uveoscleral outflow may explain a good clinical IOP lowering response despite treatment delivered to pars plana alone. The characteristic early clinical response to diode laser cyclophotocoagulation involves a profound decrease in IOP within the first few days. The origin of this phenomenon is unexplained, but it has been postulated that early inflammation may be responsible for the decrease, although the clinical level of inflammation is routinely low. Only one case of early post-treatment enucleation was examined in our study—case 8. At 2 weeks—and the level of inflammation was slight despite good IOP control, although admittedly after repeated treatments.

Almost all of the reported experimental studies of cyclophotocoagulation in animals have involved Nd:YAG laser rather than diode laser. The study of Brancato and colleagues of diode laser in rabbits examined the treated eyes at only one time point, 24 hours after treatment, whereas we studied enucleated eyes at longer intervals of 2 weeks to 4 years after cyclodestruction. The major pathology in rabbit eyes at 24 hours was coagulative necrosis of epithelium and stroma of pars plicata as well as vascular congestion and thrombosis. This correlates well with the later stages of loss of ciliary processes with pigment clumping and depletions of vessels seen in our human cases.

Injury to other ocular tissues with diode laser cyclophotocoagulation is limited. Iris base contiguous with damaged pars plicata was damaged in three patients with neovascular glaucoma and may have been related to poor diode footplate positioning, the effect perhaps enhanced by energy absorption in adjacent hyphaema (case 5). It is unlikely that this iris necrosis relates to an acute episodic rise in IOP since the pupillary margin, which is at the end of the circulation, is usually damaged in that instance, rather than iris root. Scleral damage was noted in only three cases (33%). These three had all received high energy or repeat treatments, although the case with four treatments (case 8) showed only mild scleral changes.

Histological examination in this series of patients with refractory glaucoma and enucleation has shown that diode laser is associated with much less long term inflammation of intraocular structures than Nd:YAG laser or cryotherapy (and unpublished observations). As a more focal cyclodestructive technique, contact diode laser treatment results in preservation of some ciliary processes within the treatment zone. This may contribute to an explanation of both a lack of IOP response in some cases, or a late recurrence of elevated IOP in others. Of other potential causes of IOP recovery, renewed function of secretory ciliary epithelium in areas of damage appears unlikely on histological appearances, and recovery of vascular elements is sparse and inconsistent. Histology is not helpful in determining whether variations in uveoscleral outflow or early suprachoroidal cleft formation occur and contribute to IOP changes. Evidence of sympathetic ophthal-mia or phthisis was not seen in this series.

References

P A Mckelvie, Department of Anatomical Pathology, St Vincent’s Hospital, Fitzroy, Victoria, Australia
M J Walland, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia

Correspondence to: Penelope Mckelvie, Anatomical Pathology, St Vincent’s Hospital, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia; mckelviep@svhm.org.au

Accepted for publication 3 December 2001

The authors have no proprietary interest related to this paper.

REFERENCES


